Rare Disease

Latest News

FDA Approved | Image credit: B-design - stock.adobe.com

FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema

By Julia Bonavitacola

August 21st 2025

The approval makes donidalorsen the only treatment in the US for hereditary angioedema that is an RNA-targeted prophylactic.

FDA headquarters | Image Credit: Tada Images - stock.adobe.com

FDA Issues CRL for Vatiquinone in Friedreich Ataxia, Requests More Efficacy Data

By Brooke McCormick

August 19th 2025

While the findings suggest that switching to onasemnogene abeparvovec after non–gene therapy treatments could be beneficial to patients with spinal muscular atrophy, it is not clear which patients may benefit the most from switching therapies. | Image credit: Rochu_2008 - stock.adobe.com

Switching to Gene Therapy After Nusinersen or Risdiplam May Benefit Patients With SMA

By Rose McNulty

August 15th 2025

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Women in science | Image Credit: © metamorworks-stock.adobe.com.jpeg

5 Rare Disorders Named for Pioneering Female Scientists

By Maggie L. Shaw

May 23rd 2025

More News

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

December 27th 2017

Cancer Gene Profiling Test Can Open Doors to New Targeted Therapies

Jaime Rosenberg

While FoundationOne CDx, the comprehensive companion diagnostic test for solid tumors, gives patients the ability to be accurately matched with a targeted therapy, it also has potential benefits for patients with a less common types of cancers, said Stuart Goldberg, MD, chief scientific officer, Cota, in an interview with The American Journal of Managed Care®.

FDA Approves Gene Therapy for Inherited Vision Loss

December 20th 2017

FDA Approves Gene Therapy for Inherited Vision Loss

Allison Inserro

The FDA approved Spark Therapeutics Inc.’s voretigene neparvovec-rzyl (Luxturna), the first gene therapy for inherited vision loss caused by faulty gene mutations.

Diagnosing Non-Chemotherapy Drug-Induced Neutropenia

December 16th 2017

Diagnosing Non-Chemotherapy Drug-Induced Neutropenia

Laura Joszt, MA

In a session at the 59th American Society of Hematology Annual Meeting and Exposition in Atlanta, Georgia, Brian Curtis, PhD, of the BloodCenter of Wisconsin Blood Research Institute, highlighted drugs other than chemotherapy that may cause neutropenia in patients.

December 13th 2017

New Treatment Paradigm Supersedes ABVD in Advanced Hodgkin Lymphoma: The ECHELON-1 Study

Surabhi Dangi-Garimella, PhD

Including the modified brentuximab antibody in the treatment regimen improved modified progression-free survival by 5%, although the rates of neutropenia and infections were higher in patients administered the brentuximab-containing regimen.

December 11th 2017

Balancing Hospice Utilization With the Need for Transfusion in Leukemia

Surabhi Dangi-Garimella, PhD

Is transfusion dependence a barrier to hospice utilization among older patients with leukemia who are enrolled in Medicare?

Heavy Healthcare Use Precedes Start of Acthar Injection for Patients With Rare Infantile Spasms

December 9th 2017

Heavy Healthcare Use Precedes Start of Acthar Injection for Patients With Rare Infantile Spasms

Infantile spasms are hard to diagnose, which can lead to treatment delays, according to the study authors.

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg

Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.

October 18th 2017

The Case for Eliminating the Neutropenic Diet

Although there is no scientific evidence that a specific diet reduces risk of infection in patients experiencing neutropenia, it is a common strategy in cancer care. Research presented at the 42nd Annual Congress of the Oncology Nursing Society determined that the popular neutropenic diet can be eliminated from practice.

October 13th 2017

Diagnosing and Treating Neutropenia: Q&A With Dr Daniel J. DeAngelo

Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.

September 28th 2017

Researchers Categorize Incurable Childhood Brain Tumors as Separate Cancer Types

Christina Mattina

After examining over 1000 cases of high-grade gliomas in children and young adults, researchers have split these rare brain tumors into at least 10 different subtypes, which could help clinicians choose and deliver more effective treatments.

September 13th 2017

FDA Announces Progress, Next Steps in Streamlining Orphan Drug Review Process

Christina Mattina

FDA Commissioner Scott Gottlieb, MD, announced the agency’s progress in streamlining the orphan drug review process and outlined plans to close a loophole currently hindering pediatric drug research.

September 7th 2017

Following Pembrolizumab, Nivolumab Trials in Multiple Myeloma Paused

Surabhi Dangi-Garimella, PhD

Bristol-Myers Squibb announced that the FDA has placed a clinical hold on 3 combination trials evaluating its programmed death-1 inhibitor nivolumab (Opdivo) in patients with relapsed/refractory multiple myeloma.

September 4th 2017

Healthy, but Still Hurting: Challenges of Cancer Survivorship

Laura Joszt, MA

The assumption in the United States is that once someone with cancer is cured, done with treatment, and healthy, that they are now okay. However, the reality is that survivors contend with lingering challenges that aren’t visible and make it difficult for them to ask for help or admit they need it.

September 1st 2017

5 Significant Developments With CAR-T Therapy

Surabhi Dangi-Garimella, PhD

A look at some of the major developments in the chimeric antigen receptor T (CAR-T) cell space.

September 1st 2017

What We're Reading: HHS Cuts ACA Ads; Chemical Hazard in Houston; CAR-T Treatment Price Tag

August 31st 2017

Abeona Receives Breakthrough Designation for Rare Skin Disease Gene Therapy

A gene therapy for patients with recessive dystrophic epidermolysis bullosa (RDEB), a rare skin disease that causes the skin to be very fragile and blister easily, has been granted Breakthrough Therapy designation status by the FDA.

August 30th 2017

FDA Approves Tisagenlecleucel, the First CAR-T Cell Therapy in the United States

Laura Joszt, MA

The FDA has approved the first chimeric antigen receptor-T (CAR-T) treatment, tisagenlecleucel (Kymriah), for the treatment of B-cell precursor acute lymphoblastic leukemia in certain pediatric and young adult patients. The therapy represents a new frontier in cancer care.

August 25th 2017

Case Study Identifies New Trigger for CAR-T Cell Expansion in DLBCL in JCAR017 Trial

Surabhi Dangi-Garimella, PhD

Chimeric antigen receptor (CAR)-T cells can re-expand in a lymphoma patient months after the initial infusion and can also be active against the patient’s cancer, according to a new study.

August 21st 2017

FDA Approves Besponsa for Relapsed/Refractory Acute Lymphoblastic Leukemia

Alison Rodriguez

The FDA has approved Besponsa (inotuzumab ozogamicin) for treating adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

August 18th 2017

What We're Reading: Mylan Settlement; MS Pricing Probe; Iowa Insurer's Premium Rate Hike

August 18th 2017

Understanding Patient Preferences Can Promote Adherence in MS Patients, Study Says

Alison Rodriguez

Patient preferences for multiple sclerosis therapies are important to take into account and are increasingly so as alternatives to traditional injection therapies are developed to address adherence issues.

August 10th 2017

ICER Seeks Public Comment on Scoping Document for CAR-T Treatments

Surabhi Dangi-Garimella, PhD

The Institute for Clinical and Economic Review (ICER) has released a draft version of their scoping document that will compare the clinical effectiveness and value of 2 chimeric antigen receptor (CAR)-T cell treatments being reviewed by the FDA.

August 10th 2017

Vaccine for Glioblastoma Awarded Orphan Drug Status by FDA

Christina Mattina

MimiVax announced that its immunotherapy vaccine SurVaxM, which is being tested in clinical trials for glioblastoma, has been designated an orphan drug by the FDA.

August 9th 2017

Results of Phase 2 Study Investigating Luspatercept in MDS

Alison Rodriguez

The results of a phase 2 study that explored the effects of luspatercept in patients with lower-risk myelodysplastic syndromes (MDS) were presented at the 22nd Congress of the European Hematology Association by Acceleron Pharma Inc. The company is developing the drug with Celgene.

August 7th 2017

NCI Researchers Discuss Prospects and Challenges of Treating Glioblastoma

Christina Mattina

Amidst news of Senator John McCain’s glioblastoma diagnosis, a recent discussion between 2 neuro-oncology researchers explored the reasons why this aggressive brain tumor is so difficult to manage, and outlined the ongoing investigations into possible therapies.

August 6th 2017

Study Examines Inpatient Rehabilitation for Patients With Marfan Syndrome

Alison Rodriguez

Patients with congenital heart defects, such as Marfan syndrome (MFS), are experiencing longer life expectancies due to new advances in medicine-resulting in a greater need for medical rehabilitation.

August 5th 2017

Phase 1 and Phase 2 Study Results Find Potential Treatment for Severe Cystic Fibrosis

Alison Rodriguez

Vertex Pharmaceuticals recently announced positive data from phase 1 and 2 studies of 3 triple combination regimens in cystic fibrosis patients with one F508del mutation and one minimal function mutation (F508del/Min). These results are the first to present the potential of treating the underlying cause of those with difficult-to-treat cystic fibrosis.

August 4th 2017

5 Developments With Cancer Immunotherapy

Surabhi Dangi-Garimella, PhD

There’s a lot happening in clinical practice with immunotherapy treatments: expanded indications for nivolumab and ipilimumab, biomarkers to judge patient response to combinations, and developments with CAR-T.

This Week in Managed Care: August 4, 2017

August 4th 2017

This Week in Managed Care: August 4, 2017

This week, the top managed care stories included bipartisan proposals for fixing the Affordable Care Act (ACA); FDA approved a targeted therapy for patients with acute myeloid leukemia who have a rare genetic mutation; and a study found that more patients have gained access to clinical trials after the ACA was implemented.

August 2nd 2017

ICER Seeks Comments for Proposed Changes for Orphan Drugs Assessments

Alison Rodriguez

The Institute for Clinical and Economic Review is seeking public comments on its recently released outline of proposed adaptations involving the assessment of certain treatments for ultra-rare conditions, also known as orphan drugs.

...

17 18 19 20 21 22 23 24 25

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions